NasdaqCM:DRTSMedical Equipment
Alpha Tau Medical (DRTS) Clinical Win Puts Its Pricey Valuation Back In Focus
Alpha Tau Medical (NasdaqCM:DRTS) is back in focus after reporting clinical data showing a 100% objective response rate for its Alpha DaRT plus pembrolizumab regimen in elderly head and neck cancer patients, presented at a major specialist conference.
See our latest analysis for Alpha Tau Medical.
Despite the sharp one day share price pullback of about 5.6% to US$12.50, Alpha Tau Medical still shows strong momentum, with a 30 day share price return of about 14.9% and a year to date share...